Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01353222 · ClinicalTrials.gov registry record · Phase 2
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
A Phase 2 study, sponsored by Dendreon.
- Terminated
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT01353222 is a Phase 2 study that was terminated before completion, run by Dendreon. The registered enrollment target is 142 participants.
The verdict
NCT01353222, a Phase 2 study, was terminated before completion, sponsored by Dendreon.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
This study was conducted to examine survival, disease-free survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.
Interventions
- OTHER Standard of Care
- BIOLOGICAL DN24-02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01353222
The ClinicalTrials.gov registry entry for NCT01353222 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dendreon, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT01353222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01353222 about?
NCT01353222 is a clinical study titled "DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma". This study was conducted to examine survival, disease-free survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.
What is the current status of trial NCT01353222?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2011-06. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01353222?
The interventions under investigation include: Standard of Care (OTHER), DN24-02 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01353222?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.